Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399935 | 0.86 | HTT (0.96) | HTTSMN1; SMN2PKMALDH1A1KMT2A | |
| N-Piperidinobenzamide SCHEMBL696161 | 0.85 | HTT (1.00) | HTTSMN1; SMN2PKMALDH1A1KMT2A | |
| SCHEMBL9282775 | 0.85 | HTT (1.00) | HTTSMN1; SMN2PKMALDH1A1KMT2A | |
| SCHEMBL55036 | 0.83 | HTT (0.66) | HTTCYP2D6SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL280280 | 0.83 | CYP2D6 (0.73) | HTTCYP2D6SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4959035 | 0.83 | HTT (0.66) | HTTCYP2D6SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL1664142 | 0.82 | HTT (0.51) | HTTCYP2D6SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL12629113 | 0.81 | CYP2D6 (0.71) | HTTCYP2D6SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8018069 | 0.81 | CYP2D6 (0.53) | HTTCYP2D6SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14562953 | 0.81 | HTT (0.62) | HTTCYP2D6SMN1; SMN2PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | HTT 386/4885CYP2D6 1786/4885SMN1; SMN2 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.